|Application ||WB, E|
|Calculated MW||144771 Da|
|Antigen Region||886-912 aa|
|Other Names||AF4/FMR2 family member 2, Fragile X E mental retardation syndrome protein, Fragile X mental retardation 2 protein, FMR2P, Protein FMR-2, Protein Ox19, AFF2, FMR2, OX19|
|Target/Specificity||This AFF2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 886-912 amino acids from the Central region of human AFF2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||AFF2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||RNA-binding protein. Might be involved in alternative splicing regulation through an interaction with G-quartet RNA structure.|
|Cellular Location||Nucleus speckle. Note=When splicing is inhibited, accumulates in enlarged speckles|
|Tissue Location||Brain (most abundant in hippocampus and amygdala), placenta and lung|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a putative transcriptional activator that is a member of the AF4FMR2 gene family. This gene is associated with the folate-sensitive fragile X E locus on chromosome X. A repeat polymorphism in the fragile X E locus results in silencing of this gene causing Fragile X E syndrome. Fragile X E syndrome is a form of nonsyndromic X-linked mental retardation. Alternate splicing results in multiple transcript variants.
Bensaid, M., et al. Nucleic Acids Res. 37(4):1269-1279(2009)
Brylawski, B.P., et al. Exp. Mol. Pathol. 82(2):190-196(2007)
Sharma, D., et al. Genet. Epidemiol. 20(1):129-144(2001)
Hillman, M.A., et al. J. Hum. Genet. 46(5):251-259(2001)
Musumeci, S.A., et al. Clin Neurophysiol 111(9):1632-1636(2000)
If you have any additional inquiries please email technical services at email@example.com.